Actinium Pharmaceuticals, Inc. (ATNM)
After hours:
| Previous Close | 7.90 |
| Open | 7.96 |
| Bid | 7.65 x 800 |
| Ask | 7.97 x 2200 |
| Day's Range | 7.71 - 8.07 |
| 52 Week Range | 4.00 - 10.24 |
| Volume | |
| Avg. Volume | 267,137 |
| Market Cap | 232.907M |
| Beta (5Y Monthly) | 0.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.71 |
| Earnings Date | Aug 12, 2024 - Aug 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.40 |
PR NewswireActinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the FDA clearance of an Investigational New Drug (IND) application to study Iomab-ACT for targeted conditioning prior to a bone marrow transplant (BMT), in patients with sickle cell disease. The study will be conducted in collaboration with the Columbia University and led by Markus Mapara, M.D., Ph.D
- PR Newswire
Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that the Company will participate in the 3rd Annual Targeted Radiopharmaceuticals Summit US, being held in San Diego, CA, from July 30 – August 1, 2024. Actinium's presentation titled, "Overcoming Adverse Cytogenetics, TP53, Other Mutations & Treatment Resistant Disease in Relapsed/Refractory AML Usi
ZacksIs Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
Here is how Actinium Pharmaceuticals (ATNM) and Encompass Health (EHC) have performed compared to their sector so far this year.
